DOLOMITE NEAT ID Network Study: A Prospective, Multi-site Observational Study to Define the Safety and Effectiveness of Dolutegravir Use in HIV Positive Pregnant Women
Status: Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors ViiV Healthcare
- 31 Oct 2019 Planned initiation date changed from 30 Sep 2019 to 20 Dec 2019.
- 18 Sep 2019 Planned initiation date changed from 30 Aug 2019 to 30 Sep 2019.
- 15 Aug 2019 Planned initiation date changed from 30 Jul 2019 to 30 Aug 2019.